Advanced Proteome Therapeutics Engages CRO to Escalate Testing of Promising Cancer Therapy

VANCOUVER, BC--(Marketwired - November 12, 2014) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to announce that it has entered into an agreement with one of the world's foremost contract research organizations (CRO). Now, in addition to its in-house programs and academic collaborations, APC will be able to avail itself of the CRO's high quality research models and preclinical and clinical support services to evaluate and accelerate the Company's immuno-oncology program.

As announced on September 11th, the Company's preliminary results involving testing of its D5 (APC 101) protein modification in combination with checkpoint inhibitors, were compelling -- the combination of APC 101 administered with a checkpoint inhibitor displayed statistically significant tumor growth suppression compared to the checkpoint inhibitor treatment alone in an animal model of cancer; the mice themselves were immune to subsequent re-challenge by the same tumor. Indeed, the Company has been fortunate in generating a number of molecular modifications of its core protein technology that have demonstrated the ability to retard tumor growth in an animal model of cancer, each of which possess distinct attributes. To demonstrate the potential commercial value of the Company's technology, and aid in selecting a lead compound, the CRO has been engaged to scope out the activity of the Company's molecules in commercially viable treatment models (e.g. colon, breast, lung, etc.) and evaluate their abilities to synergize with other entities to treat cancers in combination. 

APC 101 will be the subject of testing in animal models in the CRO beginning in November 2014. The review of results in December, coupled with ongoing testing of our inventory by our academic collaborators in our standard animal model, will dictate next steps: whether testing of APC 101 is pursued in animal models in diverse combinations, or improved versions of APC 101 will be tested in the same models.

"Accessing the high quality drug development services of a reliable partner is critical for APC to be able to expand its anticancer program to diverse cancers, deliver results within challenging timelines, and define our competitive advantage," comments Dr. Alexander (Allen) Krantz, President and CEO of APC.

About APC
APC has been applying its Foundation Trinity™ Technology to proteins targeted for the treatment of cancers. Advanced targeted therapies are designed to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics' market in the near future. The Company's goals are not only to employ therapy targeted for tumor cells, but also to deliver combination therapy in a single, pure therapeutic agent. To achieve this end, it has been the Company's intention to utilize a unique protein (and related systems), not only as a delivery vehicle to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface -- both key to efficient manufacturing and product development. The protein vehicle has emerged as a potential immunotherapeutic as it is implicated in activating the immune system to attack and help clear tumor cells. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry.

ON BEHALF OF THE BOARD
Alexander (Allen) Krantz
President and Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.